Home
PTGX
PTGX News

Latest Protagonist Therapeutics Inc. (PTGX) News on November 22, 2025

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates

Zacks

15 days ago

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates

Associated Press Finance

15 days ago

Protagonist Therapeutics: Q3 Earnings Snapshot

ACCESS Newswire

15 days ago

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting

Simply Wall St.

17 days ago

Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

18 days ago

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates

Zacks

18 days ago

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates

ACCESS Newswire

18 days ago

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

23 days ago

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?

MT Newswires

25 days ago

Wedbush Raises Price Target on Protagonist Therapeutics to $86 From $70, Keeps Outperform Rating

MT Newswires

25 days ago

Truist Raises Price Target on Protagonist Therapeutics to $88 From $76, Keeps Buy Rating

Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates

Zacks

25 days ago

Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates

Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals

GlobeNewswire

2 months ago

Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals

MT Newswires

2 months ago

Leerink Partners Initiates Protagonist Therapeutics at Outperform With $73 Price Target

MT Newswires

2 months ago

Protagonist Says Johnson & Johnson Submits Application to EMA for Plaque Psoriasis Treatment

ACCESS Newswire

2 months ago

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency

ACCESS Newswire

5 months ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Argus Research

5 months ago

PTGX: Lowering target price to $56.00

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera

Insider Monkey

5 months ago

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

Insider Monkey

5 months ago

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

MT Newswires

5 months ago

Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target

Argus Research

5 months ago

PTGX: Rating decreased to a HOLD

For Patients With Rare Blood Cancer, New Drug Offers Relief

The Wall Street Journal

5 months ago

For Patients With Rare Blood Cancer, New Drug Offers Relief

Exploring Three High Growth Tech Stocks In The US Market

Simply Wall St.

6 months ago

Exploring Three High Growth Tech Stocks In The US Market

MT Newswires

6 months ago

Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint

Business Wire

6 months ago

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome

Insider Monkey

6 months ago

Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome

ACCESS Newswire

6 months ago

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

Argus Research

6 months ago

PTGX: Raising target price to $49.00

Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Insider Monkey

6 months ago

Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain

MT Newswires

6 months ago

Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study

ACCESS Newswire

6 months ago

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Simply Wall St.

6 months ago

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Argus Research

7 months ago

PTGX: Rating increased to a BUY

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

Zacks

7 months ago

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

ACCESS Newswire

7 months ago

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

ACCESS Newswire

7 months ago

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

Argus Research

7 months ago

PTGX: Lowering target price to $48.00

ACCESS Newswire

7 months ago

Protagonist Therapeutics Reports Granting of Inducement Award

Argus Research

7 months ago

PTGX: Raising target price to $49.00

ACCESS Newswire

7 months ago

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

Argus Research

7 months ago

PTGX: Lowering target price to $44.00

Argus Research

8 months ago

PTGX: Lowering target price to $49.00

Argus Research

8 months ago

PTGX: Lowering target price to $54.00

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

Zacks

8 months ago

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?

Insider Monkey

8 months ago

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?

ACCESS Newswire

8 months ago

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

These 10 biotech companies are changing how we discover new drugs and treat complex diseases

FastCompany

8 months ago

These 10 biotech companies are changing how we discover new drugs and treat complex diseases

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?

Insider Monkey

8 months ago

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

Zacks

8 months ago

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why

Zacks

8 months ago

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why

PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

Zacks

8 months ago

PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

MT Newswires

8 months ago

Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success

GuruFocus.com

8 months ago

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success

J&J and Protagonist’s icotrokinra scores in Phase IIb UC study

Clinical Trials Arena

8 months ago

J&J and Protagonist’s icotrokinra scores in Phase IIb UC study

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday

Insider Monkey

8 months ago

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

Investor's Business Daily

8 months ago

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

MT Newswires

8 months ago

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires

8 months ago

Top Midday Gainers

MT Newswires

8 months ago

Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating

MT Newswires

8 months ago

Protagonist, Johnson & Johnson Say Phase 2b Icotrokinra Study Meets Primary Endpoint in Ulcerative Colitis

ACCESS Newswire

8 months ago

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

ACCESS Newswire

8 months ago

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Argus Research

9 months ago

PTGX: Rating decreased to a SELL

News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat

Simply Wall St.

9 months ago

News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Benzinga

9 months ago

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Takeda and Protagonist report topline outcomes from trial of rusfertide

Clinical Trials Arena

9 months ago

Takeda and Protagonist report topline outcomes from trial of rusfertide

MT Newswires

9 months ago

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Business Wire

9 months ago

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Protagonist says Takeda-partnered drug succeeds in rare blood cancer

BioPharma Dive

9 months ago

Protagonist says Takeda-partnered drug succeeds in rare blood cancer

Argus Research

9 months ago

PTGX: Lowering target price to $37.00

Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years

Simply Wall St.

9 months ago

Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years

Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates

Zacks

9 months ago

Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates

Associated Press Finance

9 months ago

Protagonist Therapeutics: Q4 Earnings Snapshot

MT Newswires

9 months ago

Protagonist Therapeutics' Q4 Earnings, License and Collaboration Revenue Rise

ACCESS Newswire

9 months ago

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Argus Research

9 months ago

PTGX: Raising target price to $40.00

Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now

Insider Monkey

9 months ago

Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now

Argus Research

10 months ago

PTGX: Lowering target price to $39.00

Biotech walks a 'tightrope' amid unclear funding, regulations

Yahoo Finance Video

10 months ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ACCESS Newswire

10 months ago

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025

Argus Research

10 months ago

PTGX: What does Argus have to say about PTGX?

Argus Research

10 months ago

PTGX: Raising target price to $40.00

Argus Research

10 months ago

PTGX: Lowering target price to $39.00

ACCESSWIRE

10 months ago

Protagonist Therapeutics Reports Granting of Inducement Awards

Argus Research

a year ago

PTGX: What does Argus have to say about PTGX?

ACCESSWIRE

a year ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Argus Research

a year ago

PTGX: Lowering target price to $43.00

Argus Research

a year ago

PTGX: Raising target price to $44.00

ACCESSWIRE

a year ago

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

MT Newswires

a year ago

Goldman Sachs Initiates Protagonist Therapeutics at Neutral With $47 Price Target

Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities

TipRanks

a year ago

Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities

Argus Research

a year ago

PTGX: Lowering target price to $43.00

Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Simply Wall St.

a year ago

Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 11/29/2024

MT Newswires

a year ago

Protagonist Therapeutics Insider Sold Shares Worth $5,635,430, According to a Recent SEC Filing

MT Newswires

a year ago

Protagonist Therapeutics Insider Sold Shares Worth $4,680,749, According to a Recent SEC Filing

MT Newswires

a year ago

Protagonist Therapeutics Insider Sold Shares Worth $1,414,402, According to a Recent SEC Filing

Argus Research

a year ago

PTGX: Raising target price to $47.00

ACCESSWIRE

a year ago

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

ACCESSWIRE

a year ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

Share on Social Networks: